<DOC>
	<DOCNO>NCT00814866</DOCNO>
	<brief_summary>Osteoclastic bone resorption depend capacity generate osteoclast ( osteoclastogenesis ) individual osteoclast activity . The investigator objective study effect anti-TNF therapy number osteoclast precursor peripheral blood patient Rheumatoid Arthritis , vitro osteoclastogenesis osteoclast activity treatment patient Rheumatoid Arthritis Adalimumab .</brief_summary>
	<brief_title>Bone Resorption , Osteoclastogenesis Adalimumab</brief_title>
	<detailed_description>Osteoclasts ( OCs ) cell specialize bone degradation participate bone joint destruction Rheumatoid Arthritis ( RA ) . Experimental model clearly demonstrate OCs essential local bone resorption arthritis . In RANKL knockout mouse ( 1 ; 2 ) , rat receive OPG ( 3-6 ) c-fos ( -/- ) hTNF transgenic mouse ( 7 ) induction arthritis lead inflammation bone erosion . Systemic osteoporosis important comorbidity RA ( 8 ; 9 ) . Increased systemic bone resorption due OC activation occur even early ( &lt; 2 year ) RA correlate disease activity ( 10 ) . Bisphosphonates effective prevent systemic bone loss inflammatory disease , unknown reason seem influence periarticular bone erosion joint destruction . Finally , systemic factor affect osteoclastogenesis seem present RA , show increased formation OCs bone marrow patient severe arthritis compare control ( 11 ) . TNF-alpha major pathologic mediator RA . It may induce bone resorption either directly , stimulate osteoclastogenesis ( 12 ; 13 ) indirectly , influence RANKL , OPG prostaglandin production osteoblast ( 14 ; 15 ) . These pathway may important pathophysiology several disease periodontitis , Rheumatoid arthritis osteoporosis ( 16 ; 17 ) . In mouse , TNF-alpha increase number osteoclast precursor vivo role may , however , complex implicate also osteoclastogenesis-inhibiting mechanism ( 18 ; 19 ) ; fact , certain condition , TNF-alpha may decrease osteoclastogenesis ( 20 ) , vivo effect block TNF may difficult predict model . Anti-TNF agent reduce bone destruction RA clear effect achieve since , describe precede paragraph , TNF show antagonistic effect osteoclast formation activity . Moreover , little known effect anti-TNF therapy osteoclast biology human . Working hypothesis This project base two different closely related hypothesis : 1 . Treatment anti-TNF agent ( Adalimumab case ) may reduce number circulate osteoclast precursor , vitro osteoclastogenesis vitro bone resorption . 2 . Addition Adalimumab culture medium use differentiate osteoclast vitro may inhibit osteoclastogenesis bone resorption . Objectives Osteoclastic bone resorption depend capacity generate osteoclast ( osteoclastogenesis ) individual osteoclast activity . Our objective study effect anti-TNF therapy number osteoclast precursor peripheral blood patient RA , vitro osteoclastogenesis osteoclast activity treatment patient RA Adalimumab . Research plan Trial design : As clinical trail aim studying impact anti-TNF treatment osteoclastogenesis osteoclast activity study one cohort patient RA two point begin therapy , 3 6 month , patient his/her control ( before/after study ) . The two time point introduction therapy need two reason : 1 ) The time eventual effect parameter study may reach peak known 2 ) To assure parameter measure stable time . Outcomes : Primary outcome difference follow parameter treatment Adalimumab ( 3 6 month ) : 1. number osteoclast precursor ( CD14+ ) cell peripheral blood 2. number osteoclast generate vitro 3. amount bone resorption vitro Secondary outcome : 1 . Parallel vitro differentiation assay ( number osteoclast generate amount bone resorption ) presence exogenous Adalimumab concentration range find plasma treated patient detect direct effect medication vitro osteoclastogenesis . 2. disease activity define DAS28 score ( 21 ; 22 ) 3 . Change functional status M-HAQ ( 23 ) Patient cohort : Inclusion criterion : Patients satisfy ACR Criteria RA ( 24 ) receive prescription Adalimumab rheumatologist Centre hospitalier universitaire de Sherbrooke . Patients receive anti-TNF therapy eligible 5 half-lives previous medication . Patients must willing sign inform consent . Concomitant medication anti-TNFs biologicals allow treat rheumatologist adjust best interest patient . This study , thus , impact routine treatment patient . Concomitant medication record consider final analysis . Exclusion criterion : Patients age 18 capable willing provide inform consent , patient start Adalimumab less five half life interruption previous anti-TNF therapy . Sample size statistic : The sample size calculate base distribution variance primary outcome , i.e . number osteoclast generate vitro . From population 51 normal donor laboratory number osteoclast generate 601.1 ± 156.8 osteoclasts/well ( data present 2007 annual meeting Canadian Rheumatology Association , press Journal Rheumatology ) . We consider test significance level 5 % ( α = 0.05 ) power 80 % detect difference least 100 osteoclasts/well group ( pair two-tailed t-test ) , lead total 22 patient . Considering 10 % loss due technical reason sample size establish 25 patient . Methodology Blood sample : 50 ml blood heparin collect patient 2 month begin treatment Adalimumab 3 six month first administration drug ( ± 2 week ) . DAS-28 , HAQ score , comorbidities concomitant medication determine record time cod data store secure database . Osteoclast Studies : Osteoclastogenesis : PBMCs isolate 50 ml blood Ficoll-Hypaque gradient number CD14+ OC precursor determine FACS . The whole population PBMCs plat 48-well tissue culture plat contain bone slice glass slide , cell allow differentiate 21 day presence recombinant RANKL ( 75 ng/ml ) M-CSF ( 10 ng/ml ) . The cell fix stained TRAP activity hematoxylin . The number TRAP+ cell contain three nucleus count well . Triplicates use patient . In parallel well cell incubated condition presence Adalimumab concentration comparable find vivo treatment . OC resorptive activity : For bone resorption assay , cell differentiate 21 day bone slice stain TRAP 0.2 % toluidine blue . Resorption surface area quantify use image analysis program , Simple PCI . Parellel assay do presence Adalimumab . Statistical analysis : The group intervention compare use parametric pair two-tailed test variable normal distribution non parametric test whenever appropriate . Anticipated result These study allow u determine treatment Adalimumab effect number circulate osteoclast precursor , generation osteoclast bone-resorbing activity cell . It also allow determine Adalimumab , concentration find vivo , may direct impact human osteoclastogenesis bone resorption . Perhaps importantly , correlation osteoclast result clinical parameter study may allow u insight whether eventual effect osteoclast may correlate clinical response medication , indicate possible additional mechanism action Adalimumab Rheumatoid Arthritis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Bone Resorption</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients satisfy ACR criterion Rheumatoid arthritis receive prescription Adalimumab Centre Hospitalier Universitaire de Sherbrooke . Patients 18 year old Patients unwilling unable sign inform consent Patients start Adalimumab less five halflifes interruption previous anbtiTNF therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>arthritis</keyword>
	<keyword>osteoclast</keyword>
	<keyword>bone</keyword>
</DOC>